BioAxone Announces a Second-Round Investment of $12.15 Million

BioAxone Therapeutic a Montreal-based neuroscience company, is pleased to announce the recent closing of a second-round investment of $12.15 million. Four major venture capital companies, namely T2C2/Bio2000, Solidarity Fund QFL, Investissement Desjardins and Lothian Partners 27 SARL, made the investment. BioAxone has developed a therapeutic protein, Cethrin, which received CTA (clinical trial application) and IND (investigational new drug application) approval for spinal cord injury on June 3, 2004, and Jan. 6, 2005, respectively. As of today, six patients have been enrolled.

()a href="http://www.newswire.ca/en/releases/archive/May2005/19/c1502.html" target="_blank">Canada NewsWire Group